Patents by Inventor Jan-Georg Peters

Jan-Georg Peters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of copanlisib and its dihydrochloride salt
    Patent number: 10494372
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: December 3, 2019
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Philipp Rubenbauer, Daniel Götz, Danja Großbach, Franz-Josef Mais, Heiko Schirmer, Juergen Stiehl, Kai Lovis, Andreas Lender, Martin Seyfried, Theodor Zweifel, Maurus Marty, Günter Weingärtner
  • Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
    Patent number: 10383876
    Abstract: The present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and—to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agent
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: August 20, 2019
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller
  • SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT
    Publication number: 20180282337
    Abstract: The present invention relates to a novel method of preparing copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib, copanlisib dihydrochloride, or hydrates of copanlisib dihydrochloride. The present invention also relates to copanlisib dihydrochloride hydrates as compounds.
    Type: Application
    Filed: November 5, 2015
    Publication date: October 4, 2018
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg PETERS, Philipp RUBENBAUER, Daniel GÖTZ, Danja GROßBACH, Franz-Josef MAIS, Heiko SCHIRMER, Juergen STIEHL, Kai LOVIS, Andreas LENDER, Martin SEYFRIED, Theodor ZWEIFEL, Maurus MARTY, Günter WEINGÄRTNER
  • Synthesis of copanlisib and its dihydrochloride salt
    Patent number: 10035803
    Abstract: The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: July 31, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg Peters, Jürgen Stiehl, Kai Lovis
  • SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT
    Publication number: 20170327505
    Abstract: The present invention relates to a novel method of preparing copanlisib, and copanlisib dihydrochloride, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said copanlisib.
    Type: Application
    Filed: November 5, 2015
    Publication date: November 16, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jan-Georg PETERS, Jürgen STIEHL, Kai LOVIS
  • Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
    Patent number: 9636344
    Abstract: The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin's lymphoma.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: May 2, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller
  • SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS
    Publication number: 20160193219
    Abstract: The present invention relates to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof; and to its use for the treatment of non-Hodgkin's lymphoma.
    Type: Application
    Filed: January 7, 2016
    Publication date: July 7, 2016
    Inventors: Jan-Georg PETERS, Hans-Christian MILITZER, Hartwig MÜLLER
  • SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE SALTS
    Publication number: 20140072529
    Abstract: The present invention relates:—to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;—to methods of preparing said dihydrochloride salt;—to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;—to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;—to a pharmaceutical composition comprising said dihydrochloride salt; and to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agent
    Type: Application
    Filed: March 29, 2012
    Publication date: March 13, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Jan-Georg Peters, Hans-Christian Militzer, Hartwig Müller